Breaking News

Serán Bioscience Plans New Commercial-Scale Manufacturing Facility

Announces growth transaction of more than $200M from Bain Capital Life Sciences and Vivo Capital.

Author Image

By: Charlie Sternberg

Associate Editor

Serán Bioscience, a contract development and manufacturing organization (CDMO) providing a comprehensive suite of development, analytical, and manufacturing services to pharmaceutical and biotechnology companies, has announced a strategic growth transaction of more than $200 million, which will support Serán’s continued growth and construction of a new commercial-scale manufacturing facility.   Bain Capital Life Sciences led the transaction while existing investor Vivo Capital remains a key sh...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters